GLP-1 employer coverage is frozen, not growing

About 36% of employers cover GLP-1 drugs for both diabetes and weight loss, matching last year's figure and up from 34% in 2024, according to a recent survey. The two-point gain from 2024 looks, at first read, like forward motion. The more recent comparison is the one worth holding: coverage did not move from 2025 into the current survey period, and many employers are finding ways around broader access rather than choosing to build it.

What the numbers say

A gain from 34% to 36% is the kind of data point that gets packaged as a trend. The problem is it stopped there. Coverage held flat year over year, from 2025 to the current survey period, at 36%. Two percentage points in one cycle, then nothing.

The case for sustained expansion requires the number to keep climbing. It has not.

Employers working around coverage

GLP-1 drugs have attracted serious clinical attention as obesity treatments, generating a wide public conversation about access and cost. Employer benefits design has not followed that attention into broader coverage. The survey captures a market that is familiar with the drugs but has not committed to covering them at scale for weight loss.

What's changed is the posture. The survey frames many employers as actively finding alternatives to expanded coverage, not simply declining to add it. That is a different signal than inertia.

The counterargument

Thirty-six percent is a real share of the employer market. The 2024 move from 34% to 36% shows adoption happened. Employers who added GLP-1 weight-loss coverage presumably worked through the cost modeling and concluded the benefit held.

One flat year is not a reversal. Benefits design moves in cycles, not quarters, and a number that holds can still move.

On balance

On balance, the survey leaves more unresolved than the top-line figure suggests. Coverage for GLP-1 weight-loss use has not grown in a year. Employers are working around expansion rather than into it, according to the survey. The next reading of that 36% is the one that will settle whether this is a pause or a ceiling.